A U.S. cannabis company has made a bid to acquire Aurora Cannabis Inc., a company based in Edmonton. Aurora revealed that it is setting up a special committee to evaluate the unsolicited offer from Curaleaf Holdings Inc., which aims to purchase all outstanding shares of Aurora.
Curaleaf, headquartered in Stamford, Conn. and listed on the Toronto Stock Exchange, disclosed its intentions to create a combined cannabis enterprise operating in 17 countries across Europe, North America, and other global markets. The company decided to make its bid public after unsuccessful private negotiations with Aurora’s leadership.
The proposed deal involves paying Aurora shareholders $4 US per share, along with an additional $0.75 US in cash for each Aurora share. Aurora confirmed receipt of letters from Curaleaf outlining the acquisition proposals but disputed Curaleaf’s claim that it refused to engage in discussions.
Aurora clarified that its independent director had been in recent correspondence with Curaleaf’s CEO, emphasizing the company’s focus on executing its business plan and maintaining open dialogue. The Canadian cannabis firm will establish a special committee of independent directors to assess the proposal’s viability and its impact on stakeholders.
While acknowledging Curaleaf’s interest in the potential acquisition, Aurora stated that the current offer undervalues its long-term growth prospects. Analysts at TD Cowen echoed this sentiment, emphasizing Aurora’s market leadership, product portfolio, financial strength, and regulatory expertise as drivers for creating substantial long-term value.
Curaleaf’s CEO expressed optimism about the merger, highlighting the synergies between the companies’ global distribution networks, medical cannabis operations, and production capabilities. The combined revenue of both entities exceeded $1.5 billion US in the past year, with Curaleaf expecting annual cost synergies of at least $40 million US from the proposed takeover.
The potential merger is viewed as a beneficial opportunity for both Curaleaf and Aurora shareholders, offering enhanced global exposure and capitalizing on favorable regulatory trends in the U.S. cannabis market.